Chris Cox

Chris Cox joined The Medicines Company (MDCO) in February 2016 as Executive Vice President and Chief Corporate Development Officer.  Prior to joining MDCO, Chris spent over 20 years as a corporate attorney, most recently at Cadwalader, Wickersham & Taft LLP, where he was Co-Chair of the Firm’s Corporate Group and a member of its Management Committee.  He joined Cadwalader in January 2012.  Previously, he was a Partner at Cahill Gordon & Reindel LLP.  Chris has extensive experience in a wide array of corporate, financial and business-related matters, including mergers and acquisitions, joint ventures, restructurings, spin-offs and IP licensing and monetization transactions.  He has been selected by The American Lawyer as a “Dealmaker of the Year” and was named an M&A Atlas "Top 50 Global M&A Lawyer."  He has also been recognized for his work in mergers, acquisitions and buyouts by Chambers and The Legal 500 and has been named a leading lawyer by the Lawdragon 500 Annual Guide.  Chris has been a Director of Datawatch Corporation since August 21, 2012.  He received a B.S. and J.D. from the University of Missouri, where he was a member of the Missouri Law Review.

Title: 
Executive Vice President